Peptide Cycling Chart: When to Pause Each Class
Peptide therapy is rarely meant to run forever. Some peptides need scheduled breaks to keep working. Others can be used continuously. The right cycle depends on the peptide class, your goals, and what is happening at the receptor level. Here is the practical guide to cycling, peptide by peptide.
In this article
Key Takeaways
- Cycling is not a universal rule. Growth hormone secretagogues (CJC-1295/Ipamorelin, Sermorelin) usually need scheduled breaks. Many other peptides, NAD+, MOTS-c, GHK-Cu, Glutathione, Thymosin Alpha-1, can run continuously.
- The reason GH peptides are cycled is receptor desensitization: continuous stimulation of the GHRH and ghrelin receptors makes the pituitary less responsive over time, so the peptide "stops working." A few weeks off restores sensitivity.
- A few peptides are dosed on their own logic: Epitalon by design uses 10-day pulses with months between courses; BPC-157 and TB-500 are run in courses tied to a specific healing goal, then stopped; PT-141 is used on demand, not on a schedule.
- A practical default for CJC-1295/Ipamorelin without a provider-specified schedule: 3 months on, 1 month off. The "5 days on, 2 days off" weekly pattern is the other common approach.
- When you stop a peptide that should be cycled, you do not "lose" your gains; you lose the peptide-amplified pulses while the receptors recover. Shortening the break defeats the purpose, add a non-cycling peptide during the break instead.
Cycling at a Glance
Need Cycling
GH secretagogues, sometimes repair peptides
Continuous OK
NAD+, MOTS-c, GHK-Cu, Glutathione, Thymosin α-1
Intermittent by Design
Epitalon (10-day pulses)
On-Demand Only
PT-141 (used as needed, not daily)
Course-Based
BPC-157, TB-500 (tied to recovery goal)
Reason to Cycle GH
Receptor desensitization with chronic stimulation
Why Some Peptides Need Cycles
The biological reason for cycling is receptor sensitivity. When a receptor is stimulated continuously, cells often respond by reducing the number of available receptors at the cell surface. The signal is still being sent, but fewer receivers are listening. The result is tachyphylaxis: gradual loss of effect at the same dose. This is the pattern seen with chronic continuous stimulation of the GHRH and ghrelin receptors that growth hormone peptides target.
Cycling solves this by giving receptors time to upregulate back to baseline. A few weeks off is usually enough for the GHRH and ghrelin receptors to recover full sensitivity, after which the peptide works as well as it did at the start of the previous cycle. Without cycling, patients often find that month four feels like the peptide stopped working, when what actually happened is the receptors became less responsive.
Most other peptide classes do not face the same downregulation problem. Peptides that act as cofactors (NAD+) or signal molecules to existing pathways (MOTS-c, GHK-Cu) work through mechanisms that do not produce the same chronic-stimulation desensitization. They can be run continuously without losing effect. Peptides that drive specific repair (BPC-157, TB-500) are cycled for goal-based reasons rather than receptor reasons; once the injury heals, the peptide is no longer needed.
The Cycling Chart: Which Peptides Need a Break
Use this as the quick reference; the sections below explain the reasoning peptide by peptide. "Course-based" means the peptide is run for a defined goal (a healing window, a body-composition target) and then stopped rather than maintained indefinitely.
| Peptide / Class | Cycle? | Typical Schedule | Why |
|---|---|---|---|
| CJC-1295 / Ipamorelin | Yes | 3 months on, 1 month off (or 5 days on, 2 off weekly) | Receptor desensitization with chronic stimulation |
| Sermorelin | Light | Often 6-12 months, then a 4-week pause | Short half-life keeps the stimulation naturally pulsatile |
| Tesamorelin | Light | 6-12 months continuous, then re-evaluate | Approved protocol was continuous; an optional break for off-label use |
| BPC-157 | Course-based | 4-8 weeks per injury; 8-12 weeks for gut, then stop | Most useful during active healing, not as maintenance |
| TB-500 / BPC-TB500 combo | Course-based | 4-6 weeks per recovery phase, then stop | Goal-completion, not receptor-driven |
| Epitalon | By design | 10-day pulse, then 3-6 months off, repeat | Mirrors the original Khavinson dosing |
| GHK-Cu | No | Continuous 3-6 months, then re-evaluate | Gene-expression mechanism does not desensitize |
| Thymosin Alpha-1 | No | Continuous 3-6 months (multi-year precedent exists) | No receptor downregulation; long clinical history |
| NAD+ | No | Continuous (sometimes a loading month, then maintenance) | Refills a cofactor pool, a continuous biological need |
| MOTS-c | No | Continuous 6-12 months, then re-evaluate | Mitochondrial signaling; no desensitization |
| Glutathione | No | Continuous (optional loading dose first) | Antioxidant clearance is a continuous need |
| AOD-9604 | Course-based | Run for the body-composition goal (3-6 months), then stop | Used to reach a target, not to maintain it |
| PT-141 | On demand | As needed, ~45 min before activity; no daily schedule | Not in the system continuously, so nothing to cycle |
| DSIP | No | Continuous 3-6 months, or only on poor-sleep nights | No receptor desensitization |
| Selank / Pinealon / PE-22-28 blends | No | Continuous 6-12 months | Neurological effects build with consistent use |
Growth Hormone Peptides
[CJC-1295/Ipamorelin](/blog/cjc-1295-ipamorelin-guide). The peptide most likely to need cycling. The standard protocol patterns:
— 3 months on, 1 month off. Run the full protocol for 12 weeks, then take a 4-week break before resuming. This is the most common cycling pattern in clinical practice.
— 5 days on, 2 days off (weekly). Inject Monday through Friday, take Saturday and Sunday off. Preserves weekly receptor sensitivity without longer breaks. Some providers prefer this for continuous GH support without the post-break adjustment period.
— Continuous with periodic 4-week breaks. Run continuously for 4 to 6 months, then take a 4-week break before resuming. This pattern is more aggressive and is usually used by patients with more advanced anti-aging protocols.
[Sermorelin](/blog/sermorelin-guide). Often cycled less aggressively than CJC-1295/Ipamorelin because the half-life is much shorter (about 10 minutes), so the receptor stimulation is naturally more pulsatile. Many patients run Sermorelin continuously for 6 to 12 months without a break, then take a 4-week pause.
[Tesamorelin](/blog/tesamorelin-guide). Typically run continuously for 6 to 12 months for visceral fat reduction, then evaluated. The original FDA-approved protocol for HIV lipodystrophy was continuous daily use without scheduled cycling. For off-label adult body composition use, some providers add a 4-week break every 6 months.
Practical Default
If you are starting CJC-1295/Ipamorelin and your provider has not specified a cycling schedule, the 3 months on / 1 month off pattern is the safe default. Track your response across multiple cycles to learn how your body responds.
Repair Peptides (BPC-157, TB-500)
Repair peptides are cycled based on goal completion rather than receptor sensitivity. The framing is "how long does this injury or recovery need" rather than "how long can I keep stimulating this pathway."
[BPC-157](/blog/bpc-157-guide) acute injury course. 4 to 8 weeks of daily injection at the affected site or systemically, then discontinue when healing is satisfactory. For acute soft tissue injuries (sprains, strains, minor surgical recovery), 4 weeks is often enough. For chronic conditions that have failed to heal over months, 8 weeks is more typical.
BPC-157 gut protocol. 8 to 12 weeks for gastrointestinal issues like ulcers, IBD flares, or gut healing after long antibiotic courses. Oral capsules are sometimes used instead of injection for direct gut exposure. Continuous use beyond 12 weeks is rarely more effective than a repeat course after a break.
[TB-500 / BPC-TB500 combo](/blog/bpc-tb500-guide). 4 to 6 weeks for soft tissue injury recovery. The combo product accelerates healing through complementary mechanisms (BPC-157 for angiogenesis and tendon healing, TB-500 for cell migration and inflammation modulation, see BPC-157 vs. TB-500 for the full breakdown). Most patients see meaningful improvement within the first 3 weeks and complete the course at 6.
After the initial course, repair peptides are usually paused. If symptoms return, a repeat course can be initiated rather than running indefinitely. Continuous BPC-157 or TB-500 for months at a time is rarely the right approach; the peptide is most effective during active healing, less so as a maintenance therapy.
Anti-Aging Peptides
[Epitalon](/blog/epitalon-guide). The most distinctive cycling pattern of any peptide. The original Khavinson research used 10-day pulse courses with months between courses. The standard protocol is 10 days of daily injection, then a 3 to 6 month break before the next 10-day pulse. This pattern is unusual but is supported by the published evidence and is the default recommendation from most peptide-experienced providers.
[GHK-Cu](/blog/ghk-cu-guide). Run continuously for 3 to 6 months, evaluate, and continue or pause based on response. Receptor downregulation does not occur with GHK-Cu in the same way as GH peptides because the mechanism (gene expression modulation across thousands of genes) does not depend on a specific receptor that can desensitize.
[Thymosin Alpha-1](/blog/thymosin-alpha-1-guide). Can be run continuously for 6 to 12 months. The original international clinical protocols for chronic hepatitis used multi-year continuous courses without cycling. For adult anti-aging immune support, most providers use 3 to 6 month courses with periodic re-evaluation rather than indefinite continuous use.
[NAD+](/blog/nad-plus-guide). Continuous use is standard. The peptide-class effect of NAD+ comes from restoring the cellular cofactor pool, which is a continuous biological need. There is no receptor downregulation to worry about. Some patients use higher loading doses for the first month, then reduce to a maintenance dose.
Metabolic and Energy Peptides
MOTS-c. Run continuously. The mitochondrial signaling effect that drives MOTS-c benefits does not produce receptor desensitization. Most patients run MOTS-c for 6 to 12 months and evaluate, with continuation as long as the metabolic response is meaningful. Some providers cycle MOTS-c with NAD+, alternating which one is the primary peptide for 3 month periods, though there is no strong evidence this is better than running both continuously.
Glutathione. Continuous use. The antioxidant clearance effect is needed continuously, particularly for patients with chronic oxidative stress. Some patients use higher initial doses to "load" tissue glutathione, then reduce to a lower maintenance dose.
AOD-9604. Run for the duration of the body composition goal, typically 3 to 6 months. The fat-loss effect is the primary use case; once the target body composition is reached, AOD-9604 is usually discontinued rather than continued as a maintenance peptide.
Sexual Health Peptides
PT-141. Used on demand rather than daily. Inject 30 to 45 minutes before anticipated activity, no scheduled daily dosing. There is no cycling concept because the peptide is not in the system continuously. Frequency is determined by lifestyle and clinical need, not a protocol schedule.
Some providers prescribe scheduled daily PT-141 for patients with persistent low desire, but this is the exception rather than the rule. The on-demand pattern produces the same clinical effect with much lower cost and exposure.
Sleep Peptides
DSIP. Can be run continuously without receptor desensitization. Typical patterns are 3 to 6 month courses with re-evaluation. Some patients use DSIP only on nights when sleep quality has been poor, which is functional rather than scheduled cycling.
Selank / Pinealon / PE-22-28 blends. Continuous use is common. The neurological effects build over weeks of consistent use and there is no specific cycling requirement. Many patients run a blend continuously for 6 to 12 months as part of a broader sleep and cognitive protocol.
Cycling Stacks and Combinations
When patients run multiple peptides simultaneously, the cycling schedule depends on the specific combination. Some practical patterns:
CJC-1295/Ipamorelin + MOTS-c. Cycle the GH peptide on the standard 3 on / 1 off pattern. Run MOTS-c continuously through both phases. The MOTS-c continuity helps maintain the metabolic baseline during the GH break.
BPC-157 + TB-500 (recovery stack). Run together for 4 to 6 weeks for the active recovery phase, then discontinue together. There is no benefit to staggering the breaks; the recovery window is finished or it is not.
NAD+ + Glutathione. Both run continuously. There is no cycling interaction between them because neither peptide produces receptor desensitization.
Epitalon + GHK-Cu. Epitalon on the 10-day pulse pattern with months between courses. GHK-Cu runs continuously throughout. The two peptides work on completely different mechanisms and do not need synchronized cycling. For how these and the other longevity peptides map onto the mechanisms of aging, see the anti-aging peptides guide.
Frequently Asked Questions
Related Guides
Continue reading about peptides and protocols that pair well with this guide.
Is Sermorelin FDA Approved? Yes Until 2008
Sermorelin has a unique regulatory history. It was FDA-approved in 1997 as Geref Diagnostic for testing pituitary function, and its therapeutic form (Geref) was used for pediatric growth hormone deficiency. Then the manufacturer discontinued it in 2008. Today Sermorelin is only available as a compounded medication. Here is the full story.
Is Epitalon FDA Approved? 40 Years, No US Trial
No. Epitalon has never been tested in Western clinical trials. Its entire evidence base comes from four decades of research at one Russian institute by one scientist: Vladimir Khavinson. That research includes the only evidence of telomerase activation by a synthetic peptide in human somatic cells. Here is why Epitalon has never entered the FDA pipeline and what the Russian data actually shows.
Epitalon 2026: The Peptide That Outsmarts Cell Aging
Every cell in your body has a countdown timer. It's called a telomere, a protective cap that shortens with each division until the cell can no longer divide and dies. In the 1980s, a Russian military gerontologist extracted a peptide from the pineal gland that reactivated telomerase and made human cells surpass their programmed death clock by 10 additional divisions, while staying young and healthy. The peptide was four amino acids long. In a 266-person study, it cut mortality in elderly patients up to 4.1x. In 2025, an independent lab finally confirmed the mechanism. Here's everything you need to know about Epitalon.
Ready to design a protocol?
Browse the peptide catalog, or take the PeRx health assessment and a licensed provider will recommend a cycling schedule appropriate for your goals, peptides, and history.
Medical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.
Reviewed by Dr. Cory Mellon, MD · Last reviewed May 2026